ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
2 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
92
|
55K
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
15 |
28/04/24 |
28/04/24 |
ASX - By Stock
|
92
|
55K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
11 |
27/04/24 |
27/04/24 |
ASX - By Stock
|
92
|
55K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
18 |
27/04/24 |
27/04/24 |
ASX - By Stock
|
92
|
55K
|
18
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
20 |
27/04/24 |
27/04/24 |
ASX - By Stock
|
92
|
55K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
11 |
27/04/24 |
27/04/24 |
ASX - By Stock
|
92
|
55K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
The Yankee
|
92 |
55K |
47 |
27/04/24 |
27/04/24 |
ASX - By Stock
|
92
|
55K
|
47
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
6 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
92
|
55K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
42 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
92
|
55K
|
42
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
31 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
92
|
55K
|
31
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
13 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
92
|
55K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
Valuation
|
|
Phaedrus
|
92 |
55K |
35 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
92
|
55K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
Phaedrus
|
675 |
305K |
25 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
675
|
305K
|
25
|
|
ASX - By Stock
|
MSB |
Re:
NASDAQ hot!!!
|
|
Phaedrus
|
675 |
305K |
20 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
675
|
305K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
6.9M |
17 |
24/04/24 |
24/04/24 |
ASX - By Stock
|
18K
|
6.9M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
6.9M |
36 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
18K
|
6.9M
|
36
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
6.9M |
5 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
18K
|
6.9M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Phaedrus
|
273 |
127K |
8 |
23/04/24 |
23/04/24 |
ASX - By Stock
|
273
|
127K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Phaedrus
|
273 |
127K |
3 |
21/04/24 |
21/04/24 |
ASX - By Stock
|
273
|
127K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
6.9M |
5 |
21/04/24 |
21/04/24 |
ASX - By Stock
|
18K
|
6.9M
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
6.9M |
2 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
18K
|
6.9M
|
2
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
6.9M |
3 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
18K
|
6.9M
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
6.9M |
17 |
20/04/24 |
20/04/24 |
ASX - By Stock
|
18K
|
6.9M
|
17
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Phaedrus
|
273 |
127K |
10 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
273
|
127K
|
10
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
otherperspective
|
943 |
407K |
112 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
943
|
407K
|
112
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
407K |
26 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
943
|
407K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
omnisearch
|
943 |
407K |
27 |
19/04/24 |
19/04/24 |
ASX - By Stock
|
943
|
407K
|
27
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Phaedrus
|
273 |
127K |
19 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
273
|
127K
|
19
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Phaedrus
|
273 |
127K |
20 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
273
|
127K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Mesoblast stock(rock)-take March 2024
|
|
Phaedrus
|
273 |
127K |
71 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
273
|
127K
|
71
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
407K |
13 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
943
|
407K
|
13
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
407K |
5 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
943
|
407K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
2024 Here we go again.
|
|
Phaedrus
|
943 |
407K |
52 |
17/04/24 |
17/04/24 |
ASX - By Stock
|
943
|
407K
|
52
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 3Y for Jane Bell
|
|
Phaedrus
|
38 |
19K |
26 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
38
|
19K
|
26
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Appendix 3Y for Jane Bell
|
|
Phaedrus
|
38 |
19K |
30 |
16/04/24 |
16/04/24 |
ASX - By Stock
|
38
|
19K
|
30
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Phaedrus
|
18K |
6.9M |
21 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
18K
|
6.9M
|
21
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
185K |
8 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
549
|
185K
|
8
|
|
ASX - By Stock
|
MSB |
Re:
MESO Nasdaq update
|
|
The Yankee
|
5.7K |
2.8M |
23 |
13/04/24 |
13/04/24 |
ASX - By Stock
|
5.7K
|
2.8M
|
23
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
52K |
5 |
12/04/24 |
12/04/24 |
ASX - By Stock
|
133
|
52K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
The Yankee
|
18K |
6.9M |
22 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
18K
|
6.9M
|
22
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Notifies Clinical Data Sufficient for Refiling aGVHD BLA
|
|
Phaedrus
|
1.0K |
439K |
4 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
1.0K
|
439K
|
4
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
otherperspective
|
18K |
6.9M |
53 |
11/04/24 |
11/04/24 |
ASX - By Stock
|
18K
|
6.9M
|
53
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
52K |
20 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
133
|
52K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
52K |
55 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
133
|
52K
|
55
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
The Yankee
|
133 |
52K |
35 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
133
|
52K
|
35
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
52K |
15 |
10/04/24 |
10/04/24 |
ASX - By Stock
|
133
|
52K
|
15
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
52K |
3 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
133
|
52K
|
3
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
|
|
Phaedrus
|
549 |
185K |
20 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
549
|
185K
|
20
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
Phaedrus
|
133 |
52K |
45 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
133
|
52K
|
45
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Change in substantial holding
|
|
The Yankee
|
133 |
52K |
18 |
09/04/24 |
09/04/24 |
ASX - By Stock
|
133
|
52K
|
18
|
|